Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Debt to Equity (2016 - 2026)

Cumberland Pharmaceuticals' Debt to Equity history spans 15 years, with the latest figure at $0.21 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 68.06% to $0.21 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.21, a 68.06% decrease, with the full-year FY2025 number at $0.21, down 68.06% from a year prior.
  • Debt to Equity hit $0.21 in Q4 2025 for Cumberland Pharmaceuticals, up from $0.2 in the prior quarter.
  • Over the last five years, Debt to Equity for CPIX hit a ceiling of $0.67 in Q4 2024 and a floor of $0.18 in Q1 2025.
  • Historically, Debt to Equity has averaged $0.4 across 5 years, with a median of $0.4 in 2023.
  • Biggest five-year swings in Debt to Equity: skyrocketed 81.44% in 2024 and later tumbled 69.49% in 2025.
  • Tracing CPIX's Debt to Equity over 5 years: stood at $0.35 in 2021, then rose by 27.9% to $0.45 in 2022, then fell by 2.98% to $0.44 in 2023, then soared by 52.99% to $0.67 in 2024, then tumbled by 68.06% to $0.21 in 2025.
  • Business Quant data shows Debt to Equity for CPIX at $0.21 in Q4 2025, $0.2 in Q3 2025, and $0.19 in Q2 2025.